Who are the women blazing trails in biopharma R&D and leading the fight against Covid-19? Nominate them for Endpoints' special report
One of the many inequalities the pandemic has laid bare is the gender imbalance in biomedical research. A paper examining Covid-19 research authorship wondered out loud: Where are the women?
It’s a question that echoes beyond our current times. In the biopharma world, not only are women under-represented in R&D roles (particularly at higher levels), their achievements and talents could also be undermined by stereotypes and norms of leadership styles. The problem is even more dire for women of color.
At the same time, many have made it to the top despite the odds, playing crucial and even pioneering roles in the discovery and advancement of new medicines. At Endpoints News, we believe that celebrating and spotlighting is an integral part of moving the needle on gender diversity.
We began to tell some of these stories last year in our inaugural special report on women trailblazers, who shared how they were molded into leaders, where they see the industry going, and which ideas have the best chance of leading to change in the gender status quo. The interviews, as well as the responses to them, have been illuminating.
Now’s the time for round 2.
Just like last year, we need your help noting where the women are. But we’re also doing something different: This year’s special report will have a section dedicated to women leading the Covid-19 fight. So direct us to your CEOs, CMOs, CSOs, R&D directors and chief scientists who have supercharged drug R&D and left a lasting mark at the places they’ve been. And send notes about those who are making a difference, more narrowly, for the largest public health disaster in years.
Are you ready? Email your nominee’s name, current position and your reason for nomination (plus any questions or thoughts) to email@example.com, or use this form. Nominations are open until July 27.